1 completed, 1 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow QPI-1002: new trials by email Literature Review of QPI-1002 trials Research Report on QPI-1002
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery teprasiran, Placebo - Cardiac Surgery | Phase 3 | Terminated | Quark Pharmaceuticals | 1043 | 2018-06-29 | 2021-07-16 |
| QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant QPI-1002, Placebo - Delayed Graft Function | Phase 3 | Completed | Quark Pharmaceuticals | 594 | 2016-03-01 | 2020-05-13 |
Australia (2) · Belgium (2) · Canada (2) · Czechia (2) · France (2) · Germany (2) · Spain (2) · United States (2) · Argentina (1) · Austria (1) · Brazil (1) · Netherlands (1) · New Zealand (1) · United Kingdom (1)
John Holman, M.D.,Ph.D. (1) · Nitsan Halevy, MD (1)